Quantcast

Premier Biomedical, Inc. has announced successful advances in its cancer-focused research.  Researchers successfully killed a cancer tumor in a test tube by simply removing crucial molecular compounds necessary for the cancer’s development.  This was accomplished utilizing the Felder Doctrine™: “Physically remove the pathophysiologic basis of the disease.”

Dr. Mitchell S. Felder, Chairman of Premier Biomedical, Inc.’s Scientific Advisory Board, stated: “At best, conventional methods, such as chemotherapy and many current marketed cancer-fighting drugs, can target only one single antigen, thus allowing another antigen to survive the treatment and enabling the cancer to progress.  Plus, these blockers or inhibitors often come with dangerous side effects to the patient.  Premier Biomedical aims for far greater efficacy through mixing and matching multiple cancer target antigens simultaneously.  We actually remove the pathophysiologic basis of the disease – targeting the exact cause of the disease and eliminating it – without dangerous side effects.”

Specifically, the researchers removed a specified cancer-related Interleukin from a heterogeneous mixture at a picogram (trillionth of a gram) level of accuracy.  This may open the door to a methodology for eradicating cancer tissue without the use of any other medications and/or procedures that are often accompanied by related side effects.  Further testing has resulted in the successful removal of additional critical cancer-related antigens which are important in the development, growth, and metastasis of cancer tissue.  Leukemia and lymphoma cancers were the focus of these recent successes.

 

1 Trackback or Pingback

  • [...] Premier Biomedical, Inc. has announced successful advances in its cancer-focused research. Researchers successfully killed a cancer tumor in a test tube by simply removing crucial molecular compounds necessary for the cancer’s development. This was accomplished utilizing the Felder Doctrine™: “Physically remove the pathophysiologic basis of the disease.”  [...]

Leave a Reply

Your email address will not be published. Required fields are marked *

*